Unlocking the Mystery of Carpal Tunnel Syndrome in MPS I: What You Need to Know
"A comprehensive look at the connection between Mucopolysaccharidosis I and carpal tunnel syndrome, including symptoms, diagnosis, and treatment options."
Carpal tunnel syndrome (CTS) is a condition that causes pain, numbness, and tingling in the hand and arm. It occurs when the median nerve, which runs from the forearm into the palm of the hand, becomes compressed at the wrist. While CTS is common in the general population, it's particularly prevalent in individuals with mucopolysaccharidosis I (MPS I), a rare genetic disorder.
MPS I is a lysosomal storage disorder caused by a deficiency of the enzyme alpha-L-iduronidase. This deficiency leads to the accumulation of glycosaminoglycans (GAGs) in various tissues and organs, including the cartilage, tendons, and ligaments around the wrist. The buildup of GAGs can compress the median nerve, resulting in carpal tunnel syndrome.
This article delves into the intricate relationship between MPS I and CTS, offering insights into the symptoms, diagnostic challenges, and management strategies. Whether you're a patient, caregiver, or healthcare professional, understanding this connection is crucial for early diagnosis and effective treatment, ultimately improving the quality of life for those affected by MPS I.
MPS I and Carpal Tunnel Syndrome
Mucopolysaccharidoses are inherited diseases caused by deficiencies of lysosomal enzymes, leading to progressive glycosaminoglycan accumulation in lysosomes and cellular damage. A registry-based cohort study characterized carpal tunnel syndrome in patients with mucopolysaccharidosis I using nerve-conduction examinations and records of carpal tunnel release surgery. The available source material identifies the condition as an important manifestation of MPS I but does not provide a prevalence figure here.
Screening and Surgical Treatment
Early-onset carpal tunnel syndrome is a recognized manifestation of mucopolysaccharidoses and is associated with glycosaminoglycan deposition in soft tissues. Standard treatment has been carpal tunnel release surgery using the conventional technique of dividing the transverse carpal ligament. Diagnostic accuracy can vary because there is no universally reliable reference standard for carpal tunnel syndrome diagnosis. Literature and hospital guidelines have also been reviewed to determine screening methods and frequency for patients with mucopolysaccharidosis.
From Observation to Accepted Mechanism
Patients who appear to have had carpal tunnel syndrome are depicted in surgical literature dating back at least to the mid-1800s. Although carpal tunnel syndrome is now recognized as median nerve compression at the wrist, the JAMA Neurology source notes that almost 100 years passed between the initial observations and acceptance of this pathophysiology. Historical accounts also describe cases developing after wrist trauma and immobilization in flexion and ulnar deviation.
Why is Carpal Tunnel Syndrome More Common in People with MPS I?
The underlying cause of CTS in MPS I patients is the accumulation of glycosaminoglycans (GAGs) due to the deficiency of the alpha-L-iduronidase enzyme. These GAGs deposit in various tissues, leading to thickening and stiffness, which can compress the median nerve at the wrist. This compression results in the classic symptoms of CTS, such as pain, tingling, and numbness in the hand and fingers.
- GAG Accumulation: The primary culprit is the buildup of GAGs in the tissues around the wrist.
- Flexor Retinaculum Thickening: The flexor retinaculum, a band of tissue that covers the carpal tunnel, thickens due to GAG deposition.
- Tenosynovitis: The tenosynovium, the lining of the tendons in the wrist, also thickens, further narrowing the carpal tunnel.
Current Evidence in MPS I
A 2026 current concept review describes orthopedic sequelae of MPS that can include growth deficiency, carpal tunnel compression, trigger finger, hip dysplasia, limb malalignment, C1-2 instability, and thoracolumbar kyphosis with possible spinal cord compression or tracheal obstruction. A separate 2026 retrospective cohort study included 33 patients with mucopolysaccharidosis type I born between 2001 and 2023; participants received annual screening and treatment at a specialist hospital. The study collected clinical symptoms before and after carpal tunnel release and histopathological sections of the flexor retinaculum.
Why Pediatric Diagnosis Is Difficult
Carpal tunnel syndrome is caused by entrapment of the median nerve at the carpal tunnel. Although it is the most common entrapment neuropathy in adults, it is extremely rare in children. The literature review identifies mucopolysaccharidosis as the most common non-idiopathic etiology of pediatric carpal tunnel syndrome.
Surgical and Non-Surgical Care
A Cochrane Corner commentary examines the Cochrane Review titled “Surgical versus non-surgical treatment for carpal tunnel syndrome.” The commentary approaches that comparison from a rehabilitation perspective and was produced by Cochrane Rehabilitation in agreement with the Turkish Journal of Physical Medicine and Rehabilitation. The available source material identifies the comparison and its rehabilitation focus but does not provide outcome figures or a treatment recommendation.
The Importance of Early Detection and Intervention
Given the challenges in diagnosing CTS in patients with MPS I, healthcare providers should be vigilant for early signs and symptoms. Routine screening and monitoring are essential, particularly in young children with MPS I. Early diagnosis and treatment can prevent irreversible nerve damage and improve the overall quality of life for those affected by this complex condition.
A Cautious Clinical Synthesis
MPS I-associated carpal tunnel syndrome requires careful interpretation because symptoms, testing, and disease-related tissue changes may not align neatly. A balanced clinical approach would recognize the value of screening while acknowledging that the evidence base is shaped by rare-disease cohorts and evolving diagnostic practices. Decisions about evaluation and treatment should therefore be individualized with specialist input.
Improving Detection and Follow-Up
Future work will likely focus on detecting nerve compression earlier and clarifying which monitoring strategies best identify clinically important disease. Better longitudinal evidence could help distinguish silent nerve abnormalities from symptoms that require intervention. Because MPS I is rare, coordinated specialist follow-up and multicenter research may be important for strengthening the evidence.
Rare Disease and Recurrence
Mucopolysaccharidosis type I is a rare metabolic disorder in which glycosaminoglycan accumulation can produce musculoskeletal disorders such as carpal tunnel syndrome. A retrospective cohort study described in the source material examined prevalence, timing of development, surgical recurrence, and the effect of hematopoietic treatment. These questions illustrate the broader challenge of managing a progressive systemic disorder rather than an isolated wrist problem.
Delays and Missed Symptoms
Survey-based research on the diagnostic journey of patients with MPS I found significant delays in diagnosing carpal tunnel syndrome. The source reports that enzyme replacement therapy and hematopoietic stem cell transplantation do not prevent the development of carpal tunnel syndrome. It recommends testing patients with MPS I for carpal tunnel syndrome, while noting that musculoskeletal symptoms can bring patients to rheumatologists and create diagnostic challenges.